CLDI — Calidi Biotherapeutics Share Price
Last trade - 00:00- $11.30m
- $18.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.45 | 0.04 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 24th, 2021
- Public Since
- September 10th, 2021
- No. of Employees
- 41
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 50,924,284
- Address
- 4475 Executive Drive, Suite 200, SAN DIEGO, 92121
- Web
- https://www.calidibio.com/
- Phone
- +1 8587949600
- Contact
- Stephen Jasper
- Auditors
- Mayer Hoffman & McCann P.C.
Latest News for CLDI
Upcoming Events for CLDI
Similar to CLDI
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
As of Today at 19:47 UTC, shares in Calidi Biotherapeutics are trading at $0.18. This share price information is delayed by 15 minutes.
Shares in Calidi Biotherapeutics last closed at $0.18 and the price had moved by -98.27% over the past 365 days. In terms of relative price strength the Calidi Biotherapeutics share price has underperformed the S&P500 Index by -98.62% over the past year.
The overall consensus recommendation for Calidi Biotherapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Calidi Biotherapeutics does not currently pay a dividend.
Calidi Biotherapeutics does not currently pay a dividend.
Calidi Biotherapeutics does not currently pay a dividend.
To buy shares in Calidi Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.18, shares in Calidi Biotherapeutics had a market capitalisation of $9.22m.
Here are the trading details for Calidi Biotherapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: CLDI
Based on an overall assessment of its quality, value and momentum Calidi Biotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Calidi Biotherapeutics is $2.00. That is 1004.97% above the last closing price of $0.18.
Analysts covering Calidi Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.62 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calidi Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -90.53%.
As of the last closing price of $0.18, shares in Calidi Biotherapeutics were trading -87.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Calidi Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Calidi Biotherapeutics' directors